No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study

Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was to asses...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary pharmacology (Edinburgh) 1995-04, Vol.8 (2), p.131-135
Main Authors: Graudal, Niels A., Galløe, Anders M., Plum, Inger, Milman, Nils, Clausen, Jesper O.
Format: Article
Language:English
Subjects:
Adrenergic alpha-Agonists - blood
Aged
Analysis of Variance
Calcium Channel Blockers - adverse effects
Calcium Channel Blockers - pharmacology
Calcium channel blockers, Catecholamines, Exertion, Lung disease—obstructive
Double-Blind Method
Epinephrine - blood
Humans
Isradipine - adverse effects
Isradipine - pharmacology
Lung Diseases, Obstructive - blood
Norepinephrine - blood
Physical Exertion - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was to assess the effects of the vasodilating calcium antagonist, isradipine, on resting and exercise levels of catecholamines in patients with COPD. Eighteen patients with severe respiratory insufficiency (FEV 1
ISSN:0952-0600
1522-9637
DOI:10.1006/pulp.1995.1016